Clearside Biomedical (NSDQ:CLSD) said today that it finished enrollment for the Phase 1/2 study of CLS-TA in patients with diabetic macular edema.
The Hulk trial is designed to evaluate the safety and efficacy of a suprachoroidal injection of its suspension formulation of a corticosteroid, triamcinolone acetonide, with and without an intravitreal injection of Eylea in DME patients. The Alpharetta, Ga.-based company said it expects preliminary results from the study in the 2nd half of this year.
Get the full story at our sister site, Drug Delivery Business News.